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Abstract
Only 30% of patients diagnosed with pancreatic cancer survive one year post-diagnosis. Progress
in understanding the causes of pancreatic cancer has been made, including solidifying the
associations with obesity and diabetes, and a proportion of cases should be preventable through
lifestyle modifications. Unfortunately, identifying reliable biomarkers of early pancreatic cancer
has been extremely challenging, and no effective screening modality is currently available for this
devastating form of cancer. Recent data suggest the microbiota may play a role in the disease
process, but many questions remain. Future studies focusing on the human microbiome, both
etiologically and as a marker of disease susceptibility, should shed light on how to better tackle
prevention, early detection, and treatment of this highly fatal disease.
Keywords
periodontitis; inflammation; digestive tract; pancreas
Pancreatic cancer is an aggressively lethal cancer; 94% of pancreatic cancer patients
succumb to their disease within 5 years from diagnosis. In the US, over 46,000 individuals
will be newly diagnosed with pancreatic cancer and an estimated 20,170 men and 19,420
women will die of pancreatic cancer in 2014 (1). As with many other cancers, patients who
are diagnosed with localized disease have higher survival (24% survival at 5 years),
providing a strong rationale to focus research efforts on identifying early disease. To date,
there is no screening test available for pancreatic cancer in the general population; screening
for high-risk individuals exists, but is limited to academic medical centers as various
strategies of differing effectiveness are still being evaluated (2). The obvious and urgent
need for early biomarkers of detection has led many researchers to consider and sort through
thousands of potential blood biomarkers; but to date, none have been validated for clinical
use, and potentially promising biomarkers (3) are only rarely tested in pre-diagnostic blood
samples (4). Given that protein expression in tumors is likely to vary over the course of
disease evolution (5), it will be critical to identify markers that can identify pancreatic
Correspondence to: Dominique Michaud, ScD Professor of Epidemiology Department of Epidemiology Brown University Box G-
S121-2 Providence, RI 02912 Dominique_Michaud@brown.edu Phone 401-863-6365 Fax 401-863-3713.
NIH Public Access
Author Manuscript
Cancer J. Author manuscript; available in PMC 2015 May 01.
Published in final edited form as:













cancer at early stages of development. Only those early detection biomarkers will have
translational value for screening. Understanding the etiology of a type of cancer can often
lead to new opportunities in prevention, and identification of high-risk groups. This review
will first summarize the evidence for the role of microbiota in pancreatic cancer etiology,
followed by a summary of the literature on the potential use of the microbiome as a
biomarker for early detection and screening for pancreatic cancer.
Pathogenic microbiota: evaluating evidence for a causal link
Epidemiological evidence
Understanding the etiology of cancer can lead to new opportunities for prevention and
provide new insights into the biological mechanisms leading to carcinogenesis, which can in
turn lead to new opportunities for early detection or treatment. The well-established risk
factors for pancreatic cancer include tobacco smoke, chronic pancreatitis, obesity, and types
II diabetes. All these risk factors share a commonality: they play a role in impacting the
immune response. There is a large body of evidence implicating the role of the immune
response in carcinogenesis (6), but the challenge remains to tie epidemiological evidence to
the biology of each individual cancer. With advancing technology, we are now better
positioned to ask the difficult questions; among these is examining the role that bacteria may
play in disease pathology. In contrast to some viruses, like the well characterized human
papilloma virus 16 (HPV16), bacteria do not integrate into the host DNA, but can contribute
to carcinogenesis through other pathways. The role of bacteria in carcinogenesis is being
elucidated through the extensive work undertaken to understand the relationship between H.
pylori and gastric cancer, now classified as a causal agent by the International Agency of
Cancer Research (7). We are only recently beginning to understand how this organism can
lead to gastric cancer (8), and its ability to manipulate the host immune response (9, 10).
Epidemiological studies first started to describe a link between H. pylori and gastric cancer
in the early 1990s, initially noting higher prevalence of antibodies to H. pylori in
populations with high risks of gastric cancer (11). The literature on this association has
grown exponentially in the past two decades and multiple prevention trials have been
performed while others are underway to evaluate the impact and strategies for H. pylori
eradication (12, 13). In contrast, research examining the possible association between H.
pylori and pancreatic cancer is more recent and data on this association is comparatively
sparse. The interest in H. pylori in pancreatic cancer etiology was largely initiated by
observations that individuals with a history of gastric ulcer are at increased risk of pancreatic
cancer (14).
To date, six epidemiological studies have examined the association between antibodies to H.
pylori and risk of pancreatic cancer (15-20); however, results from these studies have been
inconsistent. One of the original cohort studies to report a positive association for H. pylori
using data from the ATBC cohort study (16) recently updated their analysis including a
substantially larger number of cases (n=353) (20); the updated analysis found no overall or
strain-specific associations with pancreatic cancer risk. An effect modification by ABO
blood type (19) was reported in a large case-control study; an association between pancreatic
cancer risk and CagA-negative H. pylori seropositivity was found among individuals with
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non-O blood type but not among those with O blood type (OR = 2.78, 95% CI = 1.49 to
5.20, P = 0.0014; OR = 1.28, 95% CI = 0.62 to 2.64, P = 0.51, respectively). The authors
hypothesize that the difference in risk could be due to differences in terminal binding
antigens in gastrointestinal mucins for individuals with non-O blood type (A and B), which
influences the binding potential of the H. pylori. The same study observed no association
between CagA-positive H. pylori seropositivity and pancreatic cancer. In contrast, no effect
modification by blood type was observed in the ATBC study (20).
Other supporting evidence for the role of microbiota in pancreatic cancer etiology has arisen
from studies on periodontal disease and pancreatic cancer. The hypothesized link between
periodontal disease and pancreatic cancer stems from the knowledge that periodontal disease
gives rise to systemic inflammation and has been associated with a number of chronic
diseases (21). Periodontal disease is an oral inflammatory disease associated with gum
recession, soft tissue damage, and bone loss leading to tooth loss. A number of studies have
also reported positive associations between tooth loss, periodontal disease and orodigestive
cancers (22, 23). Porphyromonas gingivalis has been extensively studied as a periodontal
pathogen due to its unique ability to evade the immune response (24), but many other have
been linked to periodontal disease (25, 26).
The association between periodontal disease and pancreatic cancer has been examined in
three studies to date, all of which utilized prospectively collected data from large cohort
studies; all three studies reported statistically significant positive associations (27-29). The
first study to report an association between periodontal disease and pancreatic cancer
mortality was the NHANES I Epidemologic Follow-up Study, including 49 pancreatic
cancer cases. Unfortunately, adjustment for smoking was not made in this initial study
(which was exploratory), thus limiting interpretation of findings; nevertheless, a strong
positive association was noted between periodontitis at baseline and subsequent risk of fatal
pancreatic cancer (RR= 1.77, 95% CI = 0.85-1.85, compared to those with healthy
periodontium) (27). In the second study, the analysis was conducted in the Health
Professional Follow-Up Study (HPFS), a prospective cohort with data on self-reported
baseline tooth loss and periodontal disease and 16 years of follow-up (28). During that
period, 216 cases of pancreatic cancer were newly diagnosed. After adjusting for age,
smoking, diabetes, body mass index, and a number of other dietary factors, men with
periodontal disease (with tooth loss) had a 64% higher risk of pancreatic cancer compared to
those reporting no periodontal disease (with tooth loss)(95% CI =1.19-2.26). Among never
smokers, a 2-fold increase in pancreatic cancer risk was observed (RR = 2.09, 95% CI =
1.18-3.71), ruling out the possibility that the overall association was confounded by
smoking. Furthermore, the association was stronger among dentists (representing over half
of the professionals) (RR = 1.91, 95% CI = 1.31-2.78), who more accurately report history
of periodontal disease (30). The third study, an analysis using NHANES III data, reported a
4-fold increase in risk of pancreatic cancer was observed among those with severe
periodontitis (29). In the same study, elevated antibodies to P. gingivalis were associated
with a 3-fold increase risk of orodigestive cancer mortality, but a separate examination of P.
gingivalis with pancreatic cancer mortality could not be conducted due to insufficient case
numbers (29).
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While data was not available on history of periodontal disease, antibodies to various oral
pathogens were related to the risk of pancreatic cancer in a large prospective cohort (the
European Prospective Investigation into Cancer cohort - EPIC) (31). In this cohort, blood
samples were stored on over 385,000 men and women at baseline (i.e., prior to disease) and
participants were follow-up over up to 9 years in order to identify pancreatic cancer cases. A
nested case-control study of 405 pancreatic cancer cases and 410 controls was conducted,
matching cases and controls on age at blood collection, time of blood collection, fasting
status, sex, and recruitment center and a greater than 2-fold increase in risk of pancreatic
cancer was observed among participants with high levels of antibodies to a pathogenic strain
of P. gingivalis at baseline (OR = 2.38, 95% CI =1.16-4.90, comparing >200 ng/ml vs.
<200ng/ml)(31).
Mechanisms and biological plausibility for oral bacteria in causal pathway
The presence of bacteria in pancreatic tumor tissue would certainly provide support for a
direct causal link between oral bacteria and pancreatic carcinogenesis. Unfortunately,
existing data on this topic are limited. In healthy animals (e.g., feline models), bacteria can
be found in the pancreas but the spread of bacteria and colonization do not lead to infection;
invasion and infection only occur among animals with existing inflammation (pancreatitis)
(32, 33). A few studies have looked in depth at the involvement of bacteria in acute
pancreatitis in humans. These studies have reported a high number of bacteria present in the
calcified pancreatic duct epithelium and in pancreatic abscess (33-37). Some of the bacteria
isolated from pancreatic tissues are also known members of the oral microbiome (34, 35, 38,
39). Bacterial dissemination from the mouth to the pancreas may include the colon via
bacterial translocation, general circulation, biliary duct, duodenum, and the lymphatic
system (33, 40-43).
Oral bacteria are known to impact the immune response and their dissemination can lead to
systemic changes in inflammatory cytokines. Animal model data provide strong support for
the role of P. gingivalis, one of the bacterial pathogens linked to periodontal disease, in
systemic inflammation and atherosclerosis (44). In both in vitro and in vivo, P. gingivalis
shows an ability to evade the host immune activation (45-47). P. gingivalis infection of
animal models shows an involvement of toll-like receptors (TLRs) including TLR4,
involved in protective immunity (48); TLR signaling has been shown to play an important
role in human pancreatic tumors, in particular TLR4 (49, 50), thereby providing a potential
mechanistic link between microbial stimulation and pancreatic carcinogenesis. Additional
microbial mediated pro-carcinogenetic effects include nitrosamine exposure and the increase
of systemic inflammation (6, 51). Nitrosamine carcinogenic exposure is elevated in oral
cavities of patients with gum disease (52, 53) as a result of increased levels of nitrate-
reducing bacteria (53). The association between systemic inflammatory biomarkers and
periodontal disease has been noted in a number of studies, including in the above mentioned
HPFS cohort (54).
The human microbiome as indicators of cancer risk
In a recent study, the comparison of microbiota content in saliva from pancreatic cancer
cases with those of healthy controls resulted in the identification of two bacteria (Neisseria
Michaud and Izard Page 4













elongata and Streptococcus mitis) that, combined, could distinguish cases and controls with
96.4% sensitivity and 82.1% specificity (55). The discovery phase was based on 10
pancreatic cancer cases and 10 healthy controls to identify bacteria that were statistically
different by case-control status (either increased or decreased levels in patient saliva using
16S rDNA based methodologies). The identified bacteria of interest were then validated
using 28 pancreatic cancer cases, 28 healthy controls and 28 patients with chronic
pancreatitis. While this study will need a separate replication in other samples, and
validation using prediagnostic saliva samples, the suggestion that oral microbiota may
provide an easy, non-invasive biomarker of disease is highly attractive.
Measuring markers in biological samples prior to diagnosis (i.e., nested case-control study
design) provides more information on the potential use of biomarkers for early detection. In
the large EPIC cohort, antibodies to 23 oral microbiota were measured in plasma of samples
that had been stored prior to disease detection (in some cases up to 9 years prior to
diagnosis). Levels of antibodies to commensal oral bacteria were generally lower in cases
than controls and individuals with overall higher antibody levels had a significantly lower
risk of subsequent pancreatic cancer (31). These findings suggest that antibody levels might
provide a marker of disease susceptibility and may translate to a useful indicator of risk.
The impact of the immune response, including individual genetic susceptibility associated
with immune response, are critical features to the process of inflammation and pancreatic
carcinogenesis (6). The strong genetic link between the ABO locus and pancreatic cancer,
identified by genome-wide association studies (GWAS) (56, 57), may be related to the role
of ABO types in immune response. Several studies suggest that carriers of A or B alleles are
at higher risk of hepatitis B viral (HBV) infection (58) or H. pylori infection (19). The ABO
locus (9q34.2) was strongly associated with sICAM-1 concentrations, an inflammatory
adhesion receptor that facilitates leukocyte adhesion and migration across the endothelium,
in a recent GWAS analysis (59), suggesting that the histo-blood group antigens play a role
in the inflammation processes. The composition of the oral microbiome is likely to reflect
the individual immune response status, and may provide an integrated profile of
susceptibility that reflects the genetic component of the immune response, as well as the
environmental factors that influence it.
Conclusion
While the evidence is currently limited, when taken together, the epidemiological data on
periodontal disease and periodontal pathogen P. gingivalis are sufficiently consistent to
warrant larger and more comprehensive analyses to clarify the role of microbiota in the
etiology of pancreatic cancer. Furthermore, research on the oral microbiome and pancreatic
cancer may open new opportunities to develop biomarkers to identify high-risk individuals.
With technological advances which allow for the efficient and accurate measure of the oral
microbiome, we are now poised to address these exciting questions.
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